Share: NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Laidlaw Venture Partners ("LVP"), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $4 million Series A financing round for its portfolio company AerWave. AerWave offers an interventional approach to treat Asthma, COPD and advanced lung disease, which addresses a significant unmet medical need. It is targeting the addressable COPD market made up of 4 million patients in the US, and the addressable Asthma market of 2.5 million patients in the US. The Company has broad intellectual property protection in place and a seasoned, experienced executive team with a track record of value creation.